Low-grade serous ovarian cancer: lines of therapy
2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | First line | Complete cytoreductive surgery; carboplatin-paclitaxel followed by letrozole maintenance, or letrozole alone in selected patients. | 85 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Recurrent disease | Trametinib (GOG 281) or avutometinib plus defactinib for KRAS-mutant tumours; aromatase inhibitors; secondary surgery where complete resection is possible. | 85 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.